Currently out of the existing stock ratings of Matthew Biegler, 84 are a BUY (93.33%), 6 are a HOLD (6.67%).

Matthew Biegler

Work Performance Price Targets & Ratings Chart

Analyst Matthew Biegler, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 21.43% that have a potential upside of 13.86% achieved within 53 days.

Matthew Biegler’s has documented 164 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RLAY, Relay Therapeutics at 10-Sep-2024.

Wall Street Analyst Matthew Biegler

Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for CELU (CELULARITY) at 1/28/2022. The price target of $90 was fulfilled within 41 days with a profit of $47.4 (111.27%) receiving and performance score of 27.14.

Average potential price target upside

of $29.3 (61.94%) on CELU (CELULARITY).
of $29.04 (27.6%) on FATE (FATE THERAPEUTICS).
of $24.91 (42.8%) on BPMC (BLUEPRINT MEDICINES CORP).

FATE Fate Therapeutics MRKR Marker Therapeutics TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BPMC Blueprint Medicines Corp FIXX Homology Medicines FULC Fulcrum Therapeutics NKTX Nkarta VOR Vor Biopharma CELU Celularity MDNA Medicenna Therapeutics Corp TYRA Tyra Biosciences IDYA Ideaya Biosciences RLAY Relay Therapeutics PRTG Portage Biotech APTO Aptose Biosciences OLMA Olema Pharmaceuticals DAWN Day One Biopharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Edward Tenthoff (PIPER SANDLER)